A company claims to be making great progress in a potentially widespread cancer treatment.
An exploration trial revealed that the treatment may inhibit cancer cell growth in mice and clinical trials could be completed in a few years, reported the Jerusalem Post
The study has the scientific benchmark for publication in a peer-reviewed journal not yet met, said the senior physician of the American Cancer Society, Len Lichtenfeld.
The study is from Israeli scientists at Accelerated Evolution Biotechnologies Ltd. According to the news agency AEBi.
Rapid mutations in cancer may be challenging for current treatment options, but AEBi's strategy includes three or more target peptides and a potent toxin, the news agency reports.
"Instead of attacking receptors one at a time, we each attack three receptors," said the company's CEO, Ilan Morad. "Not even cancer can mutate three receptors at the same time."